Screening the Molecular Targets of Ovarian Cancer Based on Bioinformatics Analysis

Siegel R. , Ma J. , Zou Z. , Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1): 9–29.

Nolen B.M. , Lokshin A.E. Ovarian cancer screening and early detection. In: Advances in Diagnosis and Management of Ovarian Cancer. Berlin: Springer; 2014: 33–58.

Bell D. , Berchuck A. , Birrer M. ; Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353): 609–615.

Maniar K.P. , Kurman R.J. Molecular pathology of ovarian cancer. In: Molecular Surgical Pathology. Berlin: Springer; 2013: 129–149.

Fejzo M.S. , Anderson L. , von Euw E.M. Amplification target ADRM1: role as an oncogene and therapeutic target for ovarian cancer. Int J Mol Sci. 2013; 14(2): 3094–3109.

Siu M.K.Y. , Chan H.Y. , Kong D.S.H. p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients. Proc Natl Acad Sci USA. 2010; 107(43): 18622–18627.

Hisamatsu T. , Mabuchi S. , Matsumoto Y. Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary. Mol Cancer Ther. 2013; 12(7): 1367–1377.

Bowen N.J. , Walker L.D. , Matyunina L.V. Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med Genomics. 2009; 2(1): 71.

Irizarry R.A. , Hobbs B. , Collin F. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4(2): 249–264.

Diboun I. , Wernisch L. , Orengo C.A. , Koltzenburg M. Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma. BMC Genomics. 2006; 7(1): 252.

Benjamini Y. , Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995; 289–300.

Van Der Laan M.J. , Dudoit S. , Pollard K.S. Augmentation procedures for control of the generalized family-wise error rate and tail probabilities for the proportion of false positives. Stat Appl Genet Mol Biol. 2004; 3: Article 15.

O'connor J.J. , Robertson E.F. The Mactutor History of Mathematics Archive. Fife, UK: School of Mathematics and Statistics, University of St. Andrews; 2007.

Obayashi T. , Hayashi S. , Shibaoka M. , Saeki M. , Ohta H. , Kinoshita K. COXPRESdb: a database of coexpressed gene networks in mammals. Nucleic Acids Res. 2008; 36(Database issue): D77–D82.

Hermjakob H. , Montecchi-Palazzi L. , Lewington C. IntAct: an open source molecular interaction database. Nucleic Acids Res. 2004; 32(Database issue): D452–D455.

Keshava Prasad T.S. , Goel R. , Kandasamy K. Human protein reference database: 2009 update. Nucleic Acids Res. 2009; 37(Database issue): D767–D772.

Shannon P. , Markiel A. , Ozier O. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13(11): 2498–2504.

Flaherty K.T. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res. 2006; 12(7 Pt 2): 2366s–2370s.

Wachsberger P. , Burd R. , Dicker A.P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res. 2003; 9(6): 1957–1971.

Tanaka K. , Matsumoto E. , Higashimaki Y. Role of osteoglycin in the linkage between muscle and bone. J Biol Chem. 2012; 287(15): 11616–11628.

Pham D.L. , Scheble V. , Bareiss P. SOX2 expression and prognostic significance in ovarian carcinoma. Int J Gynecol Pathol. 2013; 32(4): 358–367.

Liu H. , Yan Z-Q , Li B. Reduced expression of SOX7 in ovarian cancer: a novel tumor suppressor through the Wnt/β-catenin signaling pathway. J Ovarian Res. 2014; 7(1): 87.

Skubitz K.M. , Cheng E.Y. , Clohisy D.R. , Thompson R.C. , Skubitz A.P.N. Differential gene expression in liposarcoma, lipoma, and adipose tissue. Cancer Invest. 2005; 23(2): 105–118.

Birch A.H. , Quinn M.C. , Filali-Mouhim A. , Provencher D.M. , Mes-Masson A.M. , Tonin P.N. Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes. Mol Carcinog. 2008; 47(1): 56–65.

Jiang D. , Ying W. , Lu Y. Identification of metastasis-associated proteins by proteomic analysis and functional exploration of interleukin-18 in metastasis. Proteomics. 2003; 3(5): 724–737.

Santin A.D. , Zhan F. , Bellone S. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer. 2004; 112(1): 14–25.

Tang X. , Wang J. , Liu B. , Li M. , Chen G. , Pan Y. A comparison of the functional modules identified from time course and static PPI network data. BMC Bioinformatics. 2011; 12(1): 339.

Yang G. , Rosen D.G. , Liu G. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res. 2010; 16(15): 3875–3886.

Davidson B. , Elstrand M.B. , McMaster M.T. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol. 2005; 96(1): 42–47.

Schlosshauer P.W. , Deligdisch L. , Penault-Llorca F. Loss of p16INK4A expression in low-grade ovarian serous carcinomas. Int J Gynecol Pathol. 2011; 30(1): 22–29.

Kim A. , Ueda Y. , Naka T. , Enomoto T. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res. 2012; 31(1): 14.